Welcome to Dwaey, specifically on Human Anti-D Immunoglobulin page.
This medicine contains important and useful components, as it consists of
Human Anti-D Immunoglobulin is available in the market in concentration.
Human Anti-D Immunoglobulin
Before receiving Human Anti-D Immunoglobulin, it is crucial for patients to consult their healthcare provider to determine its suitability. Important precautions include:
- Allergy to Human Immunoglobulin: Patients should inform their healthcare provider if they have any history of allergic reactions to human-derived proteins, as this could lead to hypersensitivity reactions.
- Hemolytic Reactions: In rare cases, patients may develop a hemolytic reaction (destruction of red blood cells). Close monitoring is required after administration, especially in individuals with blood type incompatibility.
- Anemia and Blood Disorders: Those with pre-existing anemia or other blood disorders may need closer monitoring, as the Anti-D immunoglobulin can impact the immune system and may exacerbate underlying conditions.
- Pregnancy: The use of Human Anti-D Immunoglobulin is generally safe during pregnancy, especially when there is a risk of Rh incompatibility. However, its administration should be managed by a healthcare provider to ensure proper dosing.
- Neonates and Infants: Care should be taken when administering this treatment to neonates, as they may be more sensitive to certain immunoglobulins.
- Renal Disease: Human Anti-D Immunoglobulin must be used cautiously in patients with kidney problems. Monitoring renal function is essential during therapy to avoid complications.
Human Anti-D Immunoglobulin is primarily used in preventing Rh sensitization in Rh-negative individuals. Its therapeutic uses include:
- Prevention of Rh Isoimmunization: It is used to prevent the development of Rh antibodies in Rh-negative women who are pregnant with an Rh-positive fetus. This condition, called Rh incompatibility, can lead to hemolytic disease of the newborn (HDN), a serious condition that can cause severe anemia, jaundice, and other complications in the baby.
- Postpartum Prophylaxis: After the birth of an Rh-positive infant, Anti-D immunoglobulin is administered to the Rh-negative mother to prevent her immune system from producing antibodies against Rh-positive cells, which could affect future pregnancies.
- Prevention of Rh Sensitization in Miscarriage or Ectopic Pregnancy: Anti-D immunoglobulin is used following a miscarriage, ectopic pregnancy, or therapeutic abortion in Rh-negative women to prevent sensitization.
- Transfusion Reactions: It may also be administered in cases of incompatible blood transfusions, where the individual receives Rh-positive blood.
Human Anti-D Immunoglobulin should not be used in the following situations:
- Known Allergic Reaction: Patients who have had a severe allergic reaction (e.g., anaphylaxis) to immunoglobulin preparations should not receive this treatment.
- Rh-negative Individuals with Rh-negative Infants: There is no indication for the administration of Anti-D immunoglobulin if the infant is also Rh-negative, as there is no risk of Rh incompatibility.
- History of Hemolytic Transfusion Reactions: Those who have a history of severe hemolytic transfusion reactions to immunoglobulins should avoid this treatment unless under strict medical supervision.
While Human Anti-D Immunoglobulin is generally safe, it can cause side effects, which should be monitored:
- Allergic Reactions: Mild allergic reactions such as rash, itching, or urticaria may occur. Rarely, more severe reactions like anaphylaxis (a severe, life-threatening allergic reaction) can occur.
- Fever: A mild fever may develop in some patients after receiving Anti-D immunoglobulin.
- Headache: Some patients may experience mild headaches following administration.
- Hemolysis: Rarely, hemolytic anemia (destruction of red blood cells) can occur, especially in individuals who are Rh-positive or have had multiple transfusions.
- Injection Site Reactions: Pain, swelling, or redness at the injection site may occur.
- Mild Flu-like Symptoms: Symptoms like chills, muscle aches, and malaise can occasionally occur but usually resolve within a few days.
- Nausea and Vomiting: Some individuals may experience nausea, particularly if the treatment is administered intravenously.
3
Human Anti-D Immunoglobulin works by binding to Rh-positive red blood cells that may have entered the bloodstream of an Rh-negative individual. Its mechanism of action includes:
- Blocking Immune Response: When an Rh-negative individual is exposed to Rh-positive blood cells (as in pregnancy, miscarriage, or transfusion), their immune system may recognize the Rh antigen and produce antibodies. Anti-D immunoglobulin prevents the immune system from recognizing Rh-positive cells, essentially neutralizing the immune response and preventing sensitization.
- Preventing Rh Isoimmunization: By binding to and marking the Rh-positive blood cells for removal, Anti-D prevents the body from producing anti-Rh antibodies. This ensures that the immune system will not attack the Rh-positive cells in future pregnancies or transfusions.
Human Anti-D Immunoglobulin can interact with other medications, including:
- Live Vaccines: The administration of live vaccines (such as yellow fever, measles, or varicella vaccines) may interfere with the immune response following Anti-D immunoglobulin administration. It is recommended to wait at least 3 months before receiving live vaccines after receiving Anti-D.
- Immunosuppressive Therapy: If a patient is receiving immunosuppressive drugs (e.g., corticosteroids or chemotherapy), the immune system may be compromised, affecting the effectiveness of Anti-D immunoglobulin.
- Blood Products: Patients who receive blood transfusions or other immunoglobulin preparations should notify their doctor, as this can affect the timing of Anti-D administration or the outcome.
The adult dose of Human Anti-D Immunoglobulin depends on the clinical scenario. Typical dosing includes:
- Postpartum Prophylaxis: 300 mcg of Human Anti-D Immunoglobulin is typically administered within 72 hours after the delivery of an Rh-positive infant in an Rh-negative mother. The exact dose may be higher if the mother has had a large blood loss.
- Miscarriage or Ectopic Pregnancy: A dose of 300 mcg is usually given to Rh-negative women within 72 hours following a miscarriage, ectopic pregnancy, or therapeutic abortion.
- Antepartum Prophylaxis: For Rh-negative women at risk of Rh sensitization, Anti-D immunoglobulin is usually administered at 28 weeks of gestation, and potentially again at 34 weeks, especially if there is any risk of fetal blood mixing (e.g., after trauma or invasive procedures like amniocentesis).
- Transfusion Reactions: If Rh-negative individuals are exposed to Rh-positive blood, they may be given Anti-D immunoglobulin based on the quantity of Rh-positive cells introduced. The dose varies and is based on the amount of Rh-positive blood involved.
Human Anti-D Immunoglobulin is generally used for pediatric patients in situations where they are at risk for Rh isoimmunization:
- Neonates and Infants: If a newborn is Rh-positive and the mother is Rh-negative, Anti-D immunoglobulin is given to the mother, not the infant. In certain cases, such as hemolytic disease of the newborn, infants may require further interventions, but Anti-D is not typically administered to them.
- Childhood Postpartum or Post-Miscarriage: Children who have been exposed to Rh-positive blood due to a miscarriage or blood transfusion may also require Anti-D immunoglobulin, but pediatric dosing will be tailored to the specific situation based on weight and clinical condition.
---
Human Anti-D Immunoglobulin is typically safe for patients with renal impairment, and no specific dose adjustments are usually required. However, it is essential to closely monitor renal function in patients with severe kidney disease or those receiving high doses. Care should also be taken if Anti-D is given to individuals with existing fluid retention or renal compromise, as they may be at higher risk for adverse effects.
Not available in a medicine form yet